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1. Introduction
In this chapter we report on the relationship between angiographic findings, measured by
coronary angiography (CA) and intravascular ultrasound virtual histology (IVUS-VH) mo‐
dalities, and indicators of vascular inflammation in the context of coronary artery disease
(CAD). We sought to explore in vivo the relationship between patient demographics, anthro‐
pometric measures, risk factors, soluble biomarkers and plaque composition or its morpho‐
logical characteristics.
The interplay of inflammatory cells, cytokines and indicators of cell death may concur to the
plaque phenotype in the context of coronary artery disease. Therefore, the lymphocyte pop‐
ulations expressing CD4 and CD8, the circulating levels of oxidized low density lipoprotein
(ox-LDL), which may be primarily originated in the atheroma, the levels of tumour necrosis
factor alpha (TNF- α) and of soluble Fas ligand (sFasL), which may reflect the inflammatory
response and vascular apoptosis, were studied.
These biomarkers would provide useful tools to improve medical diagnosis of the clinical
atheroma. Noninvasive identification of high-risk/vulnerable coronary atherosclerotic pla‐
ques is one of the ultimate goals of coronary imaging and would dramatically improve risk
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stratification of both symptomatic and asymptomatic patients [1]. Therefore, correlations be‐
tween plaque composition, bio-indicators and the severity of cardiac events may provide
unique information about plaque type to enhance the precision of clinical and laboratory
variables used to assess patients at risk of CAD.
1.1. Coronary artery disease
Coronary artery disease is still the main cause of death worldwide and coronary athero‐
thrombosis is the leading cause of death in the United States and Europe [2,3]. A large num‐
ber of individuals who die suddenly of CAD due to atherosclerosis have no previous
symptoms [4].
Atherosclerosis is a chronic pathological process of the vasculature characterized by focal arte‐
rial wall inflammation that leads to plaque build-up, intraluminal narrowing, and athero‐
thrombotic stenosis or occlusion with distal organ damage [5,6]. The atherosclerotic lesion is a
thickening of the artery intima that consists of inflammatory and smooth muscle cells [7], as
well as connective-tissue, lipids and debris [8]. The atheroma formation is initiated by an accu‐
mulation of lipid-laden cells beneath the endothelium, denominated fatty streak [9,10]. As
atherosclerosis progresses from a benign phenotype, the atheroma becomes fibrotic, with a
large necrotic core. Also, the plaque becomes more inflamed, resulting in an infiltration of mac‐
rophages and T-lymphocytes to the metabolically active fibrous cap [3]. Disintegration of foam
cells and production of matrix metalloproteinases by activated leukocytes have detrimental
consequences leading to the destabilization of lipid rich cores and the thinning of the fibrous
cap [8]. This leads to a rupture-prone thin-cap fibroatheroma. The plaque rupture may cause
arterial thrombosis, which results in a clinical spectrum of presentations ranging from sudden
cardiac death, due to coronary occlusion, to an asymptomatic event with plaque progression
[3]. In fact, the rupture of vulnerable atherosclerotic plaque is the cause of most acute coronary
syndromes, e.g. myocardial infarction and unstable angina [8,11].
Atherosclerotic plaque stability is related to histological composition however biomarkers
for the disease severity are still lacking today [12-14]. Multiple evidences link risk factors for
atherosclerosis and its complications with altered histology, including the operation of both
innate and adaptive immunity and the balance of stimulatory and inhibitory pathways that
regulate their participation in atheroma formation and complication [15].
The early involvement of monocytes and macrophages in atherosclerosis is initiated with
endothelial cell activation. Several protein mediators, specifically cytokines and chemokines,
and LDL oxidative modification [16], direct monocyte migration to the intima and promote
their maturation into macrophages, which are retained in the lesion [17,18]. These pro-in‐
flammatory monocytes propagate the innate response by expressing high levels of pro-in‐
flammatory cytokines and other macrophages mediators including metalloproteinases
[6,19,20]. Dendritic cells that populate atherosclerotic plaques can present antigens to T-cells,
which mount a cellular immune response [21]. These immune cells are also involved in
thrombosis. Coagulation proteins elicit the expression of pro-inflammatory cytokines and
mediators that interact with toll-like receptors of immune cells. These events promote endo‐
thelial cell apoptosis [22,23].
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The ox-LDL has been described as a relevant pro-atherogenic autoantigen and its inflammatory
and immunogenic activity has been implicated in atherosclerosis development and CAD [14,24].
Experimental data showed that ox-LDL is formed in the arterial wall where it is internalized by
macrophages to form foam cells, contributing to the plaque progression [14]. The co-localization
of ox-LDL with lymphocytes and monocyte-derived cells in the human atherosclerotic lesions
reinforce the pro-atherogenic and immunogenic properties of ox-LDL, which was verified in vi‐
tro [24]. Eventually, ox-LDL formed in the arterial wall is released in the circulation [13], being
their circulating levels strongly associated with angiographically documented coronary artery
disease [25]. The proximity of ox-LDL and inflammatory cells, such as lymphocyte populations,
in the atherosclerotic plaque may accelerate macrophage activity and therefore promote athero‐
genesis [26]. The T-cells expressing CD4 surface marker recognize antigens presented by den‐
dritic cells and macrophages. The T-cell expressing CD8 when activated are capable of killing
smooth muscle cells and macrophages. Both CD4 and CD8 T cells share the capacity to recognize
protein antigens bound to histocompatibility molecules on cell surfaces [27].
Thus, the in vivo identification of plaque vulnerability whether by characterizing its compo‐
nents or by providing measures of plaque-related oxidative and inflammation markers may
improve diagnostic and eventually allow the detection of vulnerable atheroma before rupture.
1.2. Coronary angiography
Since its implementation over 30 years ago, invasive coronary angiography has become the
standard clinical method for describing the coronary arteries and the “gold standard” for di‐
agnosing CAD. The use of contrast-enhanced coronary angiography has been introduced for
stenosis detection and for assessing blood flow in the epicardial arteries. The approach
based on edge-detection algorithms has also been proposed as an emerging tool for the de‐
tection, characterization, and quantification of coronary atherosclerotic plaques [11].
The increased understanding of atherosclerosis has highlighted inherent limitations of coro‐
nary angiography as a technique for the assessment of coronary atherosclerotic plaques. An‐
giography provides a 2-dimensional view of the arterial lumen, but with no visualization of
the vessel wall. Atherosclerosis primarily affects the arterial wall and since only the lumen is
displayed, angiography does not provide extensive information about the plaque [28,29]
and may obscure the true plaque burden, leading to an underestimation of plaque severity
[3]. Also, the atherosclerotic plaque initially grows in an outwardly manner, expanding to
the vessel wall, a process denominated positive remodeling. Therefore, as a result of posi‐
tive remodeling, angiography frequently fails to detect the early stages of atherosclerosis.
Although positively remodeled lesions do not restrict blood flow, they may be unstable and
may contribute to the onset of acute coronary syndromes [30]. Furthermore, because puta‐
tive sites of stenosis are compared with an apparently normal arterial segment, angiography
often fails to detect diffuse disease in which a large portion of the artery is impacted by athe‐
rosclerotic disease. Both positive remodeling and diffuse disease are common in atheroscler‐
otic progression and may be determinants of clinical outcome.
Also, the assessment of angiograms is solely visual and, consequently, subject to significant
variation in image interpretation (observer bias) which may lead to a significant underesti‐
mation of lesion severity [30].
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Assessing the atheroma dimensions by coronary angiography (CA) has been more recently
surpassed by new methods for cardiovascular imaging using ultrasound [28,29,31] and mul‐
tislice CT [32-34], which allow a more accurate and complete imaging of atherosclerotic cor‐
onary vessels.
1.3. Intravascular ultrasound
Intravascular ultrasound (IVUS), a catheter-based technique that provides high resolution
cross-sectional images of the coronary vessel in vivo, is a tomographic technique that per‐
mits two-dimensional visualization of the arterial wall and allows further characterization of
its individual layers. Thus, IVUS is a unique imaging modality for the direct examination of
vessel dimensions and arterial wall characteristics in live subjects.
The coronary artery is inspected by a catheter incorporating a miniature ultrasound trans‐
ducer, which emits high-frequency ultrasound, usually in the range of 20 to 50 MHz provid‐
ing an axial resolution of about 100–200 μm. Lateral resolution of the ultrasonic waves is less
specific and may vary depending on imaging depth and beam width, averaging around 250
μm [35].
Given their proximity to the plaque, intravascular catheters have the inherent advantage of a
high signal-to-noise ratio [3]. The information obtained through IVUS imaging depicts the
morphological characteristics of the atheromatous plaque and is used to illustrate the geomet‐
rical configuration of its layers and architecture. Most clinical centers use a pullback system to
withdraw the catheter at a constant rate of 0.5 mm/s following its initial deployment distal to
the area of interest. As the transducer is moved through the artery, ultrasonic reflections are
electronically converted to cross-sectional images [31]. This IVUS modality is called “virtual
histology” IVUS (IVUS-VH) and allows the identification of the composition of atherosclerotic
plaques by discriminating varying echolucent regions within the atheroma [12]. Four plaque
components, fibrotic, fibro-fatty, calcification and necrotic core, can be identified as they exhib‐
it a defined radiofrequency spectrum, which can be analyzed and mathematically transformed
into a color-coded representation of the plaque composition [36].
Therefore, IVUS imaging delivers precise geometric measurements of the coronary wall and
lumen and enables the identification of different types of plaques according to their content
in lipid, fibrin calcium and necrotic tissues [12,32,37,38]. The evaluation of lipid deposits
contents commonly associated to vulnerable plaques and positive remodeling has been used
to assess lesion severity [39]. In addition, three-dimensional IVUS image reconstruction is
possible and is essential for proper assessment of the longitudinal distribution of the plaque
[36], because multiple plaque morphologies varying from a fibrotic stable plaque to sites
containing large lipids/necrotic cores can be found in a single arterial segment.
Because of its methodology, IVUS is not subject to the same limitations as angiography. Not
only is IVUS more sensitive than angiography for the detection of stenosis, it can also identi‐
fy diffuse disease and positive remodeling of the vessel wall. Furthermore, since IVUS al‐
lows the identification of morphologic characteristics of vulnerable plaques, it may be
helpful in the characterization of atherosclerotic plaque formation [31,40] and in the detec‐
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tion of plaques with a high risk of spontaneous rupture [31]. However, coronary angiogra‐
phy is still regarded by many as the principal imaging technique for guiding coronary
interventions. Recently, the correlation of coronary artery geometric measurements using
both CA and IVUS has been reported [41-43], calling the attention for the value of IVUS
alone or in conjugation with VH as precise measurements of plaque geometric parameters
and tissue histological characteristics can be obtained with this modality.
2. Methods
2.1. Study design and participants
Individual data and blood samples were obtained from patients enrolled in a prospective
study performed at the Cardiology Service of Santa Marta Hospital (CHLC, Lisbon, Portu‐
gal). The study was designed to investigate the association of circulating levels of ox-LDL,
TNF-α, sFasL and T-lymphocytes with angiographic data and atherosclerotic plaque mor‐
phological and biological characteristics.
Patients, men and women aged between 56 and 71 years old with suspected and known coro‐
nary artery disease were included in the study. A total of 35 subjects were eligible to partici‐
pate: 4 patients with ST-elevation myocardial infarction (STEMI), 7 patients with non-ST
elevation myocardial infarction (NSTEMI), 11 stable angina (SA) patients, 10 unstable angina
(UA) patients and 3 silent ischemia patients (SI). All patients underwent standard diagnostic
procedures and treated accordingly. Acute coronary syndrome patients were enrolled in the
first 24 hours of hospital admission, although the time period from the onset of chest pain to the
intervention was less than 9 hours for the majority of them. Demographic information and his‐
tory, including traditional risk factors for CAD were obtained at study entry. Evaluations in‐
cluded  cardiac  testing  and  imaging,  cardiac  characteristics  and  procedures,  such  as
angioplasty and stenting. Coronary angiography and IVUS-VH data was recorded. One pre-
specified study lesion was identified in each patient. An anatomical segment containing the en‐
tirety of the study lesion was then selected, which could be easily identified based on standard
anatomical landmarks on two modalities (CA and IVUS-VH). All patients received standard
care therapy after discharge including dual antiplatelet therapy after angioplasty.
Subjects with age above 85, significant co-morbidities as peripheral artery disease or carotid
artery disease, known antecedents of malignance or infectious diseases, chronic renal insuf‐
ficiency, concurrent inflammatory disorders, malignant neoplasm or infection and previous
myocardial infarction in the previous 5 years were not enrolled. Also, patients were ineligi‐
ble if coronary anatomy was inappropriate for IVUS.
The study protocol was approved by the CHLC Ethical Committee board and all patients
signed an informed consent accepting their participation before study enrollment.
2.2. Patient characterization
All subjects were characterized demographically, clinically and biochemically (Table I).
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Diabetes was diagnosed on the basis of fasting plasma glucose concentration ≥7.0 mmol/l (126
mg/dl) or 2h plasma glucose ≥11.1 mmol/l (200 mg/dl) or confirmed as clinically known and
treated diabetes mellitus. Subjects were diagnosed hypertensive if they were documented to
have systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or were
already on anti-hypertensive therapy. Dyslipidaemia was identified in subjects who had total
serum cholesterol level ≥190 mg/dl and/or serum triglycerides ≥180 mg/dl or were on lipid-
lowering medication. Smoking was defined as the inhaled use of cigarettes, cigars or pipes in
any quantity. Subjects who smoked within the previous year were also defined as smokers.
Patients characterization
Demographics
Male sex (n, %) 23, 66
Age (y) 63 (56 – 71)
Weight (kg) 75 (67 – 80)
Height (m) 1.7 (1.6 – 1.7)
BMI (kg/m2) 27.3 (23.7 – 29)
Risk factors / Co-
morbidities
Smoking (n, %) 6, 34
Hypercholesterolemia (n, %) 25, 71
Arterial hypertension (n, %) 25, 71
Diabetes mellitus (n, %) 8, 23
Previous medication
Aspirin (n, %) 18, 51
ACE Inhibitors (n, %) 16, 46
Anti-platelets (n, %) 14, 40
β - blockers (n, %) 15, 43
Statins (n, %) 25, 7
Biochemical analysis
Total cholesterol (mg/dl) 156 (133 – 188)
LDL (mg/dl) 104 (82 – 127)
HDL (mg/dl) 36 (27 – 45)
Triglycerides (mg/dl) 85 (59 – 127)
Glucose (mg/dl) 111 (95 – 137)
Leucocytes (x103/µl) 6.8 (5.4 – 8.5)
Neutrophils (x103/µl) 4.4 (3.3 – 5.7)
Lymphocytes (x103/µl) 1.8 (1.3 – 2.7)
Monocytes (x103/µl) 0.5 (0.3 – 0.8)
Platelets (x103/µl) 190 (156 – 235)
CK (U/l) 84 (47 – 169)
CRP (mg/l) 5.3 (2.5 – 18.4)
Pro-BNP (pg/ml) 203 (64 – 916)
Table 1. Patients demographic, clinical and biochemical characterization. Results are presented in median (Q25 – Q75)
unless otherwise specified.
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2.3. Percutaneous angiography
All patients were clinically evaluated for the extension of coronary artery disease through
the characterization of lesion morphology to define the coronary stenosis, the number of dis‐
eased vessels, the thrombolysis in myocardial infarction (TIMI) risk score, which refers to
the level of coronary blood flow assessed during coronary angiography (ranging from 3 –
complete perfusion, to 0 – total occlusion), lesion length and the presence of calcium and/or
thrombi in the lesions. The number and type of stents positioned in patients undergoing cor‐
onary angiography were also recorded. A coronary stenosis was considered clinically signif‐
icant (high-grade) as a ≥70% narrowing in the luminal diameter. Multivessel disease was
defined when more than one major coronary artery presented high-grade stenosis: left ante‐
rior descending artery (LAD); right coronary artery (RCA); left circumflex artery (LCX).
Patients angiographic characterization
Stenosis (%) 87.5 (70 – 91)
Lesion length (mm) 18.5 (13– 28)
Multivessel (n, %) 6, 19
Diseased vessels (n, %)
0 4, 11
1 20, 57
2 7, 20
3 2, 6
Lesions (n, %)
0 4, 11
1 17, 49
2 6, 17
3 2, 6
4 4, 11
Culprit vessel (n, %)
LAD / TC 20, 61
RCA 11, 31
LCX 2, 6
TIMI score (n, %) 0 1, 33 26, 74
Lesion type (n, %)
A 3, 9
B 17, 49
C 2, 6
Lesion morphology (n, %) Concentric 5, 14Eccentric 20, 57
Table 2. Patients angiographic characterization. Results are presented in median (Q25 – Q75) unless otherwise specified.
The extent (severity) of CAD was assessed following a graded angiographic system based
on previous reports by others [43, 44]. The number of diseased vessels, number of lesions,
culprit lesion and TIMI were the contributing parameters. The severity score was calculated
on the basis of the sum of individual scores assigned to each parameter assuming normal
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arteries as grade “0”: a) each vessel with ≥70% stenosis lesions contributed as 2, and vessels
with <70% stenosis lesions contributed as 1; b) each lesion treated contributed as 1; c) the
most severe lesions were graded 3 when occurring in LAD, 2 in RCA and 1 in LCX; d) the
TIMI values contributed as 0 = no occlusion to 3 = total occlusion.
2.4. Intravascular ultrasound (IVUS)
The IVUS-VH acquisition was performed using a EagleEye catheter (20 MHz) at pullback
speed of 0.5 mm/sec. The IVUS data was recorded for the reconstruction of the radiofre‐
quency backscatter information using In-Vision gold commercial  software (Volcano Cor‐
poration, USA).
For each lesion, vessel and lumen area data were obtained for every cross-section through‐
out the region of interest and lesion borders were established using the leading edges of ex‐
ternal elastic lamina (EEL) and the luminal contour. Minimal lumen diameter and reference
diameter were measured and percentage of diameter stenosis was calculated. The composi‐
tion of coronary atheroma was assessed using spectral analysis of backscatter RF signals.
The percentages of fibrotic, fibro-fatty, calcified and necrotic core were assessed. Atheroma
area and volume and were obtained after EEL and lumen diameter (LD) measures were
completed at the lumen/plaque boundary and at the media/adventitia boundary in each
cross-section forming the region of interest.
Atheroma or plaque area (PA) was determined as the difference between EEL and lumen
areas. The plaque burden was calculated as the plaque cross sectional area divided by the
EEL area and multiplying by 100. IVUS measurements were recorded at three different re‐
gions-of-interest of the selected lesion: larger stenosis region cross-section and distal and
proximal cross-sections. Median values and 25% and 75% quartile intervals for the various
parameters measured and/or calculated are listed in Table 3.
2.5. Blood sampling and laboratory assays
Peripheral blood was drawn from all patients into blood collection tubes (Vacuette) with ap‐
propriate anti-coagulant, and centrifuged at 2500 rpm for 10 minutes. Serum and plasma
were collected and stored at -80ºC until analysis, for a period not exceeding 6 months. Sam‐
ples were thawed only once.
Levels of glucose, creatinine kinase, troponin T, N-terminal pro-brain natriuretic peptide
(NT-proBNP) and C-reactive protein (CRP), blood cells count and lipid profile were routine‐
ly measured in the hospital. Plasma concentrations of ox-LDL and sFasL and serum concen‐
trations of TNF-α were measured by enzyme-linked immunosorbent assays (ELISA)
commercial kits (R&D Systems).
All the assays were performed according to the manufacturer’s recommendations. Each
sample was measured in duplicate; intra-assay variation among the duplicates for all sam‐
ples was <10%.
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Lymphocyte populations were analyzed by flow cytometry (FASCalibur, BD) in whole
blood lysed with lysing solution (BD). The following antibodies were used: PerCP mouse
anti-human CD45 (2D1, BD Pharmigen), FITC mouse anti-human CD3 (HIT3a, BD Pharmi‐
gen), APC mouse anti-human CD4 (RPA-T4, BD Pharmigen), PE mouse anti-human CD8
(RPA-T8, BD Pharmigen).
Atherosclerotic plaque characterization
Stenosis (%)
Larger stenosis region 77.6 (65 – 84)
Proximal region 49 (40 – 58)
Distal region 48.1 (37 – 59.5)
Fibrotic tissue (%)
Larger stenosis region 58.5 (51 – 75)
Proximal region 61.7 (48 – 75.5)
Distal region 59 (43 – 74.5)
Fibro-fatty tissue (%)
Larger stenosis region 9.6 (6.4 – 18)
Proximal region 13 (5 – 17.5)
Distal region 9 (4.7 – 20)
Calcified tissue (%)
Larger stenosis region 11 (2.7 – 17)
Proximal region 6 (0.3 – 14.2)
Distal region 12.8 (0.5 – 22)
Necrotic core (%)
Larger stenosis region 16.5 (8 – 22)
Proximal region 17.4 (8 – 24)
Distal region 16.5 (10 – 24)
Lumen diameter (mm)
Minimum 2.1 (1.8 – 2.3)
Maximum 2.4 (2.1 – 3)
Median 2.2 (1.9 – 2.7)
area (mm2) 3.8 (2.9 – 5.1)
External elastic lamina diameter (mm)
Minimum 4.3 (4 – 4.6)
Maximum 4.9 (4.5 – 5.1)
Median 4.6 (4.2 – 4.9)
area (mm2) 17.2 (15 – 19)
Plaque area (mm2) 13 (10 – 15)
Plaque burden (%) 77.4 (65 – 84)
Table 3. Atherosclerotic plaque measurements obtained by IVUS-VH. Results of the plaque morphology and
composition are presented in median (Q25 – Q75).
2.6. Statistical analysis
Data  were  summarized  and  represented  (box-plots)  as  median  and  inter-quartiles  25%
and 75% (Q25-Q75) for continuous variables and as proportions for categorical variables.
Non-continuous variables were analyzed using a 2x2 table and χ2 test. Continuous varia‐
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bles,  such  as  plaque  measures  at  proximal,  distal  and  larger  stenosis  region  cross-sec‐
tions  of  the  plaque,  transformed  into  categorical  variables  based  on  median  values.
Differences between classes of variables were compared using a Mann-Whitney test.  As‐
sociations  between variables,  angiographic  data  and IVUS measures  were evaluated us‐
ing non-parametric Spearman correlations.
The calculations were performed using SPSS (v. 19.0, IBM 2010) and linear regressions were
made using OriginLab (v. 7.5 SR6, OriginaLab Comp, 2006).
3. Results
The atherosclerotic plaque physical characteristics and composition obtained by IVUS were
studied and related with the severity of CAD following CA scores. These parameters were
also associated with plaque-related oxidative and inflammation bio-indicators measured in
the blood. The inter-relations between the parameters measured are described below.
3.1. Analysis of plaque components along the lesion
The composition of the plaque along its length in terms of fibrotic, fibro-fatty, necrotic and
calcified tissues assessed by IVUS-VH can be inferred from data listed in Table 3. Measure‐
ments were carried out along the plaque at three plaque regions. Therefore, larger stenosis
region, proximal and distal cross-sections were studied.
The variations observed between proximal, distal and larger stenosis region cross-sections
did not reach statistical significance, although major variations were also observed in fibro-
fatty and calcified tissues. To further analyze the plaque composition, the associations be‐
tween the fibrotic, fibro-fatty, calcified and necrotic components of the plaque were
assessed.
In the overall, high fibrotic and fibro-fatty tissue contents were correlated to low content of
calcified tissue and low necrotic core (Fig. 1).
The necrotic core content was positively correlated with calcified tissue (r=0.675, p<0.001).
The correlation values were more representative in the region with larger stenosis, although
the associations were observed in proximal and distal cross-sections.
Categorizing the plaque necrotic core and calcified tissue contents by the median value,
it was confirmed that these two components were significantly associated with the fibrot‐
ic and fibro-fatty tissues. Plaques with large areas of necrotic core (≥16.5%) had low per‐
centage  of  fibrotic  (p=0.001)  and  fibro-fatty  (p=0.002)  tissues  and  these  levels  were
significantly  different  from  those  in  plaques  with  necrotic  core  <16.5%.  Moreover,  the
percentage of calcium content increased in plaques with necrotic core content ≥16.5% rel‐
ative to plaques with necrotic core below 16.5% (p=0.001) (Fig. 2). These differences were
valid and equally significant along the plaque length, i.e.  for distal,  proximal and larger
stenosis region cross-sections.
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However, when the plaque components were analyzed relative to the calcified tissue con‐
tent of plaques (cut-point and median value of 11%) only the plaque fibrotic content could
be discriminated in the larger stenosis region (Q25-Q75=58.8-77.5% fibrotic tissue for calci‐
fied tissue <11%; Q25-Q75=33.1-58.7% fibrotic tissue for calcified tissue ≥11%; p<0.001).
Figure 1. Correlation of necrotic core (a and b) and calcified tissue (c and d) with fibrotic tissue (r=-0.677, p<0.001 and
r=-0.743, p<0.001, respectively) and fibro-fatty tissue (r=-0.562, p<0.001, r=-0.421 and p=0.012, respectively) in the
larger stenosis region. Solid line represents the linear regression, black dashed lines represent 95% confidence bands
and grey dashed lines represent prediction bands.
Figure 2. Box-plots of plaque content in fibrotic (a), fibro-fatty (b) and calcified (c) tissues according to the necrotic
core levels <16.5% and ≥16.5% in the larger stenosis region.
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3.2. Association between plaque components and plaque morphology
Measures of the EEL diameter and area, lumen diameter and area, plaque area and plaque
burden were related with the plaque composition in order to assess whether the correlations
between these parameters could identify plaque types. It was observed that associations be‐
tween morphology and components of the plaque varied along the lesion. The relationship
between the plaque content in calcified and fibrotic tissues and plaque morphology was on‐
ly verified in proximal cross-sections of the plaques.
It was observed that the calcified tissue content was positively correlated with the EEL di‐
ameter (r=0.525, p=0.001), the EEL area (r=0.478, p=0.004) and plaque area (r=0.442, p=0.008)
in proximal cross-sections (see Fig. 3).
Figure 3. Correlation of calcified tissue content in the proximal region with EEL maximum diameter (a) and plaque
area (b). Solid line represents the linear regression, black dashed lines represent 95% confidence bands and grey dash‐
ed lines represent prediction bands.
Also in the proximal region of the plaques, the fibrotic content discriminated plaque sizes as
expressed by the EEL diameter and area. Both EEL diameter and area were significantly
higher for fibrotic tissue percentages below median value (<59%) by report to plaques with
fibrotic tissue percentages above median (p=0.041) (Fig. 4).
Figure 4. Variations of EEL diameter (a) and area (b) according to fibrotic content <59% and ≥59% in the proximal region.
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3.3. Coronary angiography data versus IVUS measures
The IVUS-derived measures of coronary atherosclerotic plaques were evaluated having into
account the severity score established with angiographic data. Severity of CAD was found
to be unambiguously associated to vessel lumen decrease and increased plaque burden. The
severity score was negatively correlated with the plaque geometry IVUS VH-derived meas‐
ures, such as lumen diameter (r=-0.402, p=0.038) and lumen area (r=-0.419, p=0.03), and posi‐
tively correlated with plaque burden (r=0.496, p=0.009) as can be depicted in Fig. 5.
Figure 5. Correlation of angiographic severity with IVUS-derived measures of the atherosclerotic plaque: a) lumen di‐
ameter; b) lumen area; and c) plaque burden. Solid line represents the linear regression, black dashed lines represent
95% confidence bands and grey dashed lines represent prediction bands.
3.4. Association of soluble biomarkers and T-cells with IVUS and angiography derived
measures
The  relationship  between  the  levels  of  indicators  of  oxidation  and  inflammation  in  the
blood  circulation  with  IVUS-  and  angiography-derived  measures  of  the  atherosclerotic
plaque  was  examined  with  the  aim  of  establishing  relevant  associations  between  bio‐
markers and plaque type.
Indicators of the inflammatory process associated to cell activation and apoptosis, such as
TNF-α and sFasL, were determined. Also the concentration of ox-LDL in circulation was as‐
sessed as a measure of plaque outflow and inflammation. The variations observed in the
concentration levels of these parameters were studied relative to the plaque IVUS-derived
measures and angiographic data and severity score.
Several associations were observed between the plaque morphology and components, such
as fibrotic, fibro-fatty and necrotic core, with CD4+ and CD8+ T-cell populations and TNF-α,
sFasL and ox-LDL concentrations in the blood circulation. Due to the limited number of pa‐
tients enrolled in this prospective study and to improve statistical results enabling the con‐
current evaluation of IVUS and angiographic data, including the severity score, IVUS
variables (see variables listed in Table 3) were categorized using the median value as cut-off
point.
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Following this procedure, and in what concerns soluble biomarkers, it was observed that
sFasL, TNF-α and ox-LDL levels in circulation were strongly associated to the median val‐
ues of lumen and plaque dimensions.
The concentration of TNF-α significantly increased for large plaque areas, as expressed by
EEL diameter and area (p=0.05 in both cases), whereas sFasL concentrations increased with
diminished lumen diameters (p=0.017), as can be depicted in Fig. 6.
Figure 6. Box-plot representation of the TNF-α and sFasL concentrations relative to indicators of plaque dimensions: a)
EEL diameter categories <4.6 mm and ≥4.6 mm; b) EEL area categories <17.2 mm2 and ≥17.2mm2; c) Lumen diameter
categories <2.1 mm and ≥2.1 mm
The concentrations of ox-LDL in plasma were significantly associated with plaque area as
can be depicted in Fig. 7. Large plaque areas, above median value (area ≥13 mm2), were as‐
sociated with high ox-LDL concentrations whereas plaque areas below 13 mm2 were associ‐
ated with low ox-LDL concentrations, and the differences between median concentration
values of ox-LDL in the two groups were significant (p=0.039).
Figure 7. Box-plot representation of ox-LDL concentrations according to plaque area categories <13 mm2 and ≥13
mm2.
Concerning the plaque components, only the necrotic content assessed in the plaque region
with larger stenosis could be associated with TNF-α concentration in circulation. High con‐
centrations of TNF-α were associated with low necrotic core contents contrasting with the
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significantly lowered TNF-α concentrations (p=0.016) observed in plaques with large necrot‐
ic cores (≥16.5%) (Fig. 8)
Figure 8. Box-plot representation of TNF-α concentrations according to the necrotic core categories in the larger
stenosis region, <16.5 % and ≥16.5 %.
In what concerns T-cell CD3+ populations expressing CD4 and CD8, it was observed that the
percentage of T-cells expressing CD3CD8 were associated with the plaque dimensions (T-
cell CD3+CD8+ vs EEL diameter r=-0.518, p=0.019; T-cell CD3+CD8+ vs EEL area r=-0.530,
p=0.016). T-cells, both CD3+CD4+ and CD3+CD8+, were correlated with the plaque fibrotic
and fibro-fatty tissue components along the plaque length, i.e. from distal to proximal re‐
gions. Likely, CD3+CD4+ lymphocytes were positively correlated with fibrotic tissue
(r=0.579, p=0.009) whereas CD3+CD8+ cells were negatively correlated (r=-0.481, p=0.037) (see
Fig. 9 a and c).
Figure 9. Correlation between plaque fibro-fatty and fibrotic tissue content and CD4+ and CD8+ T lymphocytes. Solid
line represents the linear regression, black dashed lines represent 95% confidence bands and grey dashed lines repre‐
sent prediction bands.
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An opposite relationship was found between fibro-fatty tissue component and CD3+CD4+
lymphocytes  (Fig.  9  b  and  d).  The  CD3+CD4+  lymphocytes  were  negatively  correlated
with  fibro-fatty  tissue  (r  =-0.671,  p=0.002)  and  CD3+CD8+  were  positively  correlated
(r=0.698, p=0.001).
4. Discussion
This prospective study showed that plaque composition is related to plaque morphology
and these  characteristics  were  associated with the  concentration of  biomarkers  in  blood
circulation.
Plaques with higher content in necrotic core showed lower fibrotic and fibro-fatty contents
and larger areas of calcified tissue. Increased EEL diameter and area were associated to larg‐
er fibrotic and calcium contents, linking these two components to plaques protruding in the
vessel wall rather than high-stenosis regions. Together these observations suggest that pla‐
que vulnerability is not strictly linked to high-grade stenosis. Also the angiographic disease
severity score was associated with plaque burden. This is in agreement with previous stud‐
ies demonstrating that plaque ruptures typically occur in large and complex plaques [1,30],
and that coronary calcification is associated to acute coronary syndromes [37] and independ‐
ently predicts all-cause mortality in CAD in addition to traditional risk factors [46]. Prior
studies reported that shear stress and circumferential wall stress play an important role in
plaque rupture [47]. Sano et al. [31] demonstrated that the percentage of fibrous area was the
most sensitive parameter for classifying the plaques causing acute coronary syndrome. Also
the percentage of lipid area was significant in the classification of vulnerable plaques [31].
Evidences are accumulating by coronary angiography and IVUS and other imaging modali‐
ties showing that plaque complexity associates to vulnerable plaques [11,31,37]. Therefore,
to differentiate vulnerable plaques from stable plaques, the fragile part of the atheromatous
plaque is of major interest and both tissue characteristics of coronary plaques and mechani‐
cal stresses on coronary plaques should be taken into account.
Plaque rupture is related to the process in which fibrous caps over lipid core become fragile
[3]. Several in vitro studies support that continuous inflammatory stimulus in the plaque
driven by the infiltration of monocytes, macrophages and T-lymphocytes in the lesion, ulti‐
mately lead to disintegration of foam cells, and release of cytokines, such as TNF-α, and ma‐
trix metalloproteinases [6,7,18-20]. All this causes the destabilization of plaque lipid rich
cores and the thinning of the fibrous cap [3,8].
We have preciously demonstrated [48] that the susceptibility of a plaque to rupture is not
strictly linked to significant stenosis. This prospective study supports our previous findings
as positive associations between plaque dimensions i.e., EEL diameter and area independent
of high-stenosis regions, and the concentrations of TNF-α were found. TNF-α is involved in
endothelial cells activation and in the inflammatory response amplification [9,20]. Increasing
levels of this pro-inflammatory cytokine promote a continuous systemic inflammatory stim‐
ulation that can trigger and/or amplify local inflammatory responses and therefore express
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the extent of vascular inflammation. Also the relationship found between TNF-α concentra‐
tion in blood and the percentage of necrotic core area suggests an association between an
exacerbation of inflammation and the thinning of the fibrous cap with increases of fibrous
and fibro-fatty areas as plaque evolves [30,31].
In addition the process of apoptosis is an important mechanism in the pathophysiology of
atherosclerosis. Atherosclerotic plaques include large numbers of apoptotic cells and related
receptors, such as FasL, which is a type II membrane protein that induces apoptosis when it
binds to its membrane receptor Fas. FasL is expressed by activated T lymphocytes, as well as
endothelial cells [49]. It was observed in this study that decreases of lumen diameter as oc‐
curring in disease exacerbation, favored the elevation of sFasL in circulation. This supports
the view that one of the control mechanisms elicited by FasL in CAD may be the prevention
of inflammation by destruction of the activated inflammatory cells invading vascular tissues
via FasL/Fas-mediated apoptosis [49,50]. In fact, in this study the percentage of T-cells ex‐
pressing CD4 and CD8 were associated to the percentage of fibrous and fibro-fatty area rein‐
forcing the notion that Th1 cellular immunity is taking place during the disease process [6].
Also, the opposite relationship between the percentage of CD4+ and CD8+ T-cells and the
plaque percentage of fibrous and fibro-fatty areas, as observed in this study call the atten‐
tion for the balanced action of these immune cells in CAD. However, the role of specific im‐
mune responses has remained unclear. Evidence is accumulating that T-cells homing the
vessel wall contribute to inflammation [6,9] and that T-cell expressing CD4 promote athero‐
sclerosis particularly when activated by LDL modified by oxidative processes [26,27]. The T-
cells expressing CD8, when activated, trigger caspase pathways. However, CD4+ and CD8+ T
produce different effectors molecules and then effect different cells and pathways, although
redundancy of mechanisms has been described pointing to the importance of lymphocyte
homeostasis in disease.
The positive association of plaque area with ox-LDL concentrations in plasma can also be
considered a marker of plaque instability and/or plaque rupture [51,52] in addition to dis‐
ease severity. Extensive experimental data shows that ox-LDL is formed in the arterial wall
[14,16] contributing to the plaque progression. It is accepted that ox-LDL in circulation is ori‐
ginated in the vessel wall, being their circulating levels strongly associated to angiographi‐
cally documented CAD [25]. Increases in plaque area, and therefore in regions where lumen
decreases relative to circumferential EEL, may favor plaque outflow. In these regions the
vessel wall is exposed to shear stress that may contribute to endothelial denuding and pla‐
que cap erosion [47].
The current forms of imaging enable atherosclerosis assessment at the later stage when the
vascular morphology has changed dramatically. However, the evaluation of plaque charac‐
teristics by angiography and IVUS-VH was associated to circulating biomarkers levels, and
these indicators may reflect plaque vulnerability. The in vivo identification of plaque vulner‐
ability whether by characterizing its components or by providing measures of oxidative and
inflammation markers may improve diagnostic and eventually allow the detection of vul‐
nerable atheroma before rupture. The relations among the plaque components – fibrotic, fi‐
bro-fatty calcified and necrotic core – and plaque dimensions, may be important in the
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characterization of the plaque and in the assessment of its development. Also, circulating
ox-LDL, sFasL, TNF-α and lymphocyte populations may be viable targets to follow as they
may reflect the global extend of atherosclerosis and may provide useful information on pa‐
tient’s evolution, together with quantitative angiography-derived plaque parameters. The
approach may be incorporated in carefully designed clinical studies for the assessment of
coronary atherosclerosis.
5. Study limitations
This prospective study is a single-centre study that has a number of limitations. The small
number of patients enrolled did not allow association of parameters with clinical presenta‐
tion. The measurements of biomarkers that entered into the study do not reflect chronic cir‐
culating levels, as more than 50% of patients presented with acute coronary syndromes
(STEMI, NSTEMI and UA), which transiently alters levels of inflammatory biomarkers.
Some of the measurements may be confounded by concomitant treatments (medication,
stenting, etc.), which could not be estimated due to the reduced number of patients. We also
wish to emphasize that all angiography and IVUS studies are limited to the analysis of a rel‐
atively short segment of coronary arterial tree that does not fully reflect disease characteris‐
tics elsewhere. The results obtained of plaque components were not confirmed by histology
or other diagnostic modalities, such as optical coherent tomography.
6. Conclusions
The present study using angiography and IVUS-VH revealed that the atherosclerotic plaque
components and dimensions were related to the concentration of biomarkers in the blood
circulation. We reported on the vascular tissue characteristics that may be associated with
vulnerable plaques and the incremental value of biomarkers in addition to invasive imaging
modalities.
The association of ox-LDL, sFasL and TNF-α circulating levels with lumen dimension and
plaque dimension suggest that these indicators may express not only plaque rupture but
plaque vulnerability as well. Also the association of TNF-α and T lymphocytes expressing
CD4 and CD8 with plaque percentage of fibrous, fibro-fatty, and necrotic core areas may
contribute to an in vivo assessment of vascular inflammation and vulnerable plaques and
their detection before rupture.
The results  suggest  that  these  biomarkers  have clinical  implications  for  identifying vul‐
nerable plaques as well as vulnerable patients. Further studies are needed to evaluate the
impact of these biomarkers and angiography and IVUS-VH derived measures on clinical
presentation.
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